ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.933,86
-0,08%
S&P 500
5.297,32
0,26%
US Dollar vs BRL
5,288
0,71%
Bitcoin
70.912,00
3,08%
Brent Oil
77,545
-0,76%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Brooklyn ImmunoTherapeutics Inc (BTX)

  7. Brooklyn ImmunoTherapeutics Inc (BTX) Notícias

BTX

Brooklyn ImmunoTherapeut... (BTX)

Brooklyn ImmunoTherapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BTX
DataHoraFonteTítuloCódigoCompanhia
11/05/202317:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
10/05/202307:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202308:02Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202308:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202307:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
25/04/202310:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/04/202317:31Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202318:15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202318:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/12/202218:31Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
16/12/202219:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
14/12/202218:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
06/12/202220:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
02/12/202219:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
11/10/202209:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
26/07/202208:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
17/06/202218:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/06/202208:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Board ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
31/05/202208:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
27/05/202217:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-QNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
19/05/202209:23GlobeNewswire Inc.Amarin Announces Appointment of New Directors and Board Leadership ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
29/04/202217:35Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
21/04/202208:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular MedicinesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202218:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202217:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
01/04/202207:31Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
09/03/202218:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/03/202210:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/01/202209:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of DirectorsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
13/01/202210:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property PortfolioNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BTX

Seu Histórico Recente

COIN
DICEEUST
TRONbetDice
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados